Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
about
Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.Treatment of Clostridium difficile infection: recent trial results.Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One RegionTherapy of Clostridium difficile infection: perspectives on a changing paradigm.Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.[Clostridium difficile infection : What is currently available for treatment?]New antibiotics in clinical trials for Clostridium difficile.Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.
P2860
Q34044442-DD56628C-F8A2-4EC6-B721-5D510AFE8841Q34455320-0059710B-00D7-483F-A0F8-6463A8509409Q34710368-5C92A650-5004-454D-BDB5-08D15E93CB76Q35076880-FCB7BA91-86D8-4413-9812-771A1489D696Q36996846-C1224F0E-9AEF-40DE-A269-95279A078C22Q38139991-E3830CA7-0366-41E9-A6DC-05628B4D917DQ38719092-08F51667-0CE1-42F1-B4D9-6D8F4DCF3FBDQ38751212-73252AD7-BE5B-4D46-9CD4-FEC9B1A6C01DQ40279012-C0CE1F06-2594-4148-8910-9BE4AC87ECFEQ40475060-1788429E-E822-4CE5-9B7F-7EA67BF7766BQ40615409-605BEAA0-DFE7-4958-BADE-9A6AAD2F796DQ40683812-9465B91E-324F-416B-83A0-F377ED943D0FQ40916483-F882C1DB-F045-40D1-B687-8726471AAE37Q41331732-477A5111-4E11-4098-B4D1-011383E8F732Q55405974-9F7ABF5C-45BF-4377-8C9D-72356F649100
P2860
Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en-gb
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@nl
type
label
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en-gb
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@nl
prefLabel
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en-gb
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@nl
P2093
P2860
P356
P1476
Antimicrobial activity of LFF5 ...... and therapeutic implications.
@en
P2093
ECDIS Study Group
Ingrid M J G Sanders
Martijn P Bauer
Sylvia B Debast
P2860
P304
P356
10.1093/JAC/DKT013
P407
P577
2013-02-18T00:00:00Z